经典型与变异型毛细胞白血病患者的COVID-19
研究前瞻性监测503例毛细胞白血病(HCL)与变异型HCL(HCLv)患者,50%(253/503)有COVID-19证据,其中210例PCR或快速抗原检测阳性;死亡2例,死亡率约1%;正常B细胞减少与较低刺突抗体水平(P=0.0094)和较长恢复时间(P=0.0036)相关。
要点
- 503例HCL/HCLv患者中50%(253例)有COVID-19证据,210例检测阳性。
- 死亡2例,死亡率约1%,绝大多数患者恢复顺利。
- 正常B细胞减少与较低刺突抗体水平(P=0.0094)及较长恢复时间(P=0.0036)相关。
核心结论
- 在大规模HCL/HCLv队列中,COVID-19死亡率相对较低(约1%),后遗症不常见,近期治疗后正常B细胞低者恢复时间更长。
研究设计与样本
- 前瞻性监测迄今最大规模HCL/HCLv队列(n=503,其中HCL 238例、HCLv 15例),通过症状、抗体和PCR和/或抗原阳性监测COVID-19。
- 试验注册号为NCT01087333和NCT04362865。
主要发现
- 50%(253/503)患者有COVID-19证据,其中210例(83%)PCR或快速抗原检测阳性。
- 43例无阳性检测者均有核衣壳抗体提示COVID-19暴露,其中7例无回忆症状、36例有轻微症状。
- 210例阳性者中,2020年23例、2021年46例、2022年129例、2023年12例。
- 175例在COVID-19前0.4至429个月(中位66个月)开始HCL/HCLv治疗,132例末次抗CD20单克隆抗体在0.2至229个月(中位63个月)前。
- 2例死亡,包括一名年轻女性在无疫苗可用时一线克拉屈滨后2个月开始利妥昔单抗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hairy cell leukemia (HCL), similar to its variant HCLv, is a B-cell malignancy associated with decreased humoral immunity. We prospectively monitored the largest cohort of patients with HCL/HCLv to date (n = 503) for COVID-19 by symptoms, antibody, and polymerase chain reaction (PCR) and/or antigen positivity. Fifty percent (253 of 503) of the patients with HCL/HCLv (238 HCL and 15 HCLv) had evidence of COVID-19, with 210 (83%) testing positive by PCR or rapid-antigen test. Of the 43 patients without positive tests, all had nucleocapsid antibodies indicating COVID-19 exposure, 7 recalled no symptoms, and 36 had mild symptoms. Of the 210 who tested positive, 23, 46, 129, and 12 cases occurred in 2020, 2021, 2022, and 2023, respectively. Among them, 175 began treatment for HCL/HCLv 0.4 to 429 (median, 66) months before, and 132 had their last dose of anti-CD20 monoclonal antibody 0.2 to 229 (median, 63) months before. Two patients died, including a young woman who began rituximab 2 months after first-line cladribine before vaccine availability. Nearly all patients with HCL/HCLv recovered uneventfully from COVID-19 including those without vaccination or those with significant immunosuppression and recent treatment. However, decreased normal B cells from HCL or treatment was associated with lower spike antibody levels as a response to COVID-19 (P = .0094) and longer recovery time (P = .0036). Thus, in a large cohort of patients with HCL/HCLv and in the first to determine relationships between COVID-19 outcome and immune markers, mortality was relatively low (∼1%), sequelae were uncommon, and recovery from COVID-19 was longer if normal B cells were low after recent treatment. The trials are registered at www.clinicaltrials.gov as #NCT01087333 and #NCT04362865.
引用
- Kreitman RJ, Yu T, James L, et al. COVID-19 in patients with classic and variant hairy cell leukemia. Blood Adv. 2023. PMID: 37729613. doi:10.1182/bloodadvances.2023011147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。